Biostax Past Earnings Performance
Past criteria checks 0/6
Biostax has been growing earnings at an average annual rate of 27%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been declining at an average rate of 96.9% per year.
Key information
27.0%
Earnings growth rate
57.4%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -96.9% |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Biostax makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -2 | 1 | 1 |
| 30 Sep 23 | 0 | -2 | 1 | 0 |
| 30 Jun 23 | 0 | -4 | 1 | 0 |
| 31 Mar 23 | 0 | -1 | 1 | 0 |
| 31 Dec 22 | 0 | -4 | 1 | 0 |
| 30 Sep 22 | 0 | -3 | 1 | 0 |
| 30 Jun 22 | 0 | 2 | 1 | 0 |
| 31 Mar 22 | 0 | 0 | 1 | 0 |
| 31 Dec 21 | 0 | 4 | 1 | 0 |
| 30 Sep 21 | 0 | 3 | 1 | 0 |
| 30 Jun 21 | 0 | 4 | 1 | 0 |
| 31 Mar 21 | 0 | 3 | 1 | 0 |
| 31 Dec 20 | 0 | 2 | 1 | 0 |
| 30 Sep 20 | 0 | 2 | 2 | 0 |
| 30 Jun 20 | 0 | -3 | 2 | 0 |
| 31 Mar 20 | 0 | -3 | 2 | 0 |
| 31 Dec 19 | 0 | -3 | 2 | 0 |
| 30 Sep 19 | 0 | -3 | 2 | 0 |
| 30 Jun 19 | 0 | -5 | 3 | 0 |
| 31 Mar 19 | 0 | -8 | 4 | 0 |
| 31 Dec 18 | 0 | -8 | 4 | 0 |
| 30 Sep 18 | 0 | -11 | 5 | 0 |
| 30 Jun 18 | 0 | -10 | 5 | 0 |
| 31 Mar 18 | 0 | -5 | 4 | 0 |
| 31 Dec 17 | 0 | -7 | 5 | 0 |
| 30 Sep 17 | 0 | -9 | 5 | 0 |
| 30 Jun 17 | 0 | -11 | 6 | 1 |
| 31 Mar 17 | 0 | -15 | 8 | 1 |
| 31 Dec 16 | 0 | -20 | 9 | 0 |
| 30 Sep 16 | 0 | -20 | 10 | 1 |
| 30 Jun 16 | 0 | -20 | 10 | 0 |
| 31 Mar 16 | 0 | -18 | 9 | 1 |
| 31 Dec 15 | 0 | -14 | 9 | 1 |
| 30 Sep 15 | 0 | -22 | 10 | 1 |
| 30 Jun 15 | 0 | -29 | 14 | 2 |
| 31 Mar 15 | 0 | -33 | 16 | 3 |
| 31 Dec 14 | 0 | -48 | 24 | 7 |
| 30 Sep 14 | 0 | -82 | 54 | 13 |
| 30 Jun 14 | 0 | -91 | 54 | 19 |
| 31 Mar 14 | 0 | -109 | 63 | 23 |
| 31 Dec 13 | 0 | -106 | 61 | 22 |
| 30 Sep 13 | 0 | -234 | 75 | 20 |
Quality Earnings: BTAX is currently unprofitable.
Growing Profit Margin: BTAX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BTAX is unprofitable, but has reduced losses over the past 5 years at a rate of 27% per year.
Accelerating Growth: Unable to compare BTAX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BTAX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: BTAX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.